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Cross-talk between apoptosis and survival signaling pathways is crucial for regulating tissue processes and mitigating
disease. We report that anoikis—apoptosis triggered by loss of extracellular matrix contacts—activates a CD95/Fas-
mediated signaling pathway regulated by receptor-interacting protein (RIP), a kinase that shuttles between CD95/Fas-
mediated cell death and integrin/focal adhesion kinase (FAK)-mediated survival pathways. RIP’s death domain was
critical for RIP and Fas association to mediate anoikis. Fas or RIP attenuation reduced this association and suppressed
anoikis, whereas their overexpression had the reverse effect. Overexpressing FAK restored RIP and FAK association and
inhibited anoikis. Thus, RIP shuttles between CD95/Fas death and FAK survival signaling to mediate anoikis.
INTRODUCTION
Although communication between cell death and survival
signaling pathways is critical for the regulation of many
cellular and tissue processes, the molecules that mediate this
cross-talk have not been well explored. Nuclear factor
(NF)-B induces the expression of antiapoptotic proteins
and inhibits cell death pathways (Wang et al., 1996, 1998);
however, other specific molecules that directly shuttle be-
tween cell death and survival processes have not been iden-
tified. We sought to explore this realm by examining the
communication between the cell death receptors and inte-
grin-mediated prosurvival signals. Death receptors such as
tumor necrosis factor (TNF) receptor-1, DR3, DR4, DR5, and
Fas/CD95 contain a cytoplasmic death domain and trigger
apoptosis upon binding to their cognate ligands or specific
agonistic antibodies. Activation of death receptors, such as
Fas/CD95 leads to the formation of a death-inducing signal-
ing complex (Krammer, 1999, 2000). Cancer cells, including
squamous cell carcinoma (SCC) cells, constitutively express
death receptors, such as Fas, and undergo apoptosis in re-
sponse to treatment with Fas ligand (FasL) or Fas agonistic
antibody (Moers et al., 1999; Shibakita et al., 1999). Signal
transduction pathways for death receptors are well studied,
and many signaling molecules are known to mediate death
receptor-induced apoptosis (Peter and Krammer, 1998).
However, the role of death receptors in extracellular matrix
(ECM)-regulated anoikis, a form of apoptosis induced by
loss of cell–ECM contacts, has not been explored.
Focal adhesion kinase (FAK) is important in signal trans-
duction pathways that regulate cell survival and thereby
tumorigenesis. Its expression is enhanced in laryngeal SCC
(Aronsohn et al., 2003) and invasive colon and breast tumors
(Owens et al., 1995). Different FAK domains are involved in
its binding to cell surface integrin receptors and in recruiting
to focal adhesions other proteins that mediate survival sig-
nals. Phosphorylation of FAK mediates downstream signal-
ing events that regulate survival (Schlaepfer et al., 1994).
Also, overexpression of constitutively active FAK rescues
epithelial cell lines from anoikis (Frisch et al., 1996), whereas
inhibition of FAK by antisense techniques triggers apoptosis
(Xu et al., 1996). Numerous studies have shown a protective
role for FAK in apoptosis (Schaller, 2001). In addition, FasL
and Fas are constitutively expressed in SCC, and SCC cells
undergo apoptosis upon treatment with a FAS agonistic
antibody (Moers et al., 1999; Shibakita et al., 1999). Moreover,
detachment of SCC cells from the ECM leads to suppression
of FAK-mediated survival signaling, resulting in anoikis
(Zhang et al., 2004). We hypothesize that anoikis in these
cells is regulated by cross-talk between FAK survival path-
ways and death receptor-mediated cell death pathways.
However, the mediators and the mechanisms of this cross-
talk are not known.
Receptor-interacting protein (RIP), a kinase that encodes a
unique domain with homology to serine/threonine and ty-
rosine kinases, is constitutively expressed in many tissues
(Stanger et al., 1995). RIP interacts with Fas/CD95 in yeast
and cancer cell death pathways (Stanger et al., 1995).
Through its interactions with the death receptors TNF
receptor 1, TNF receptor-associated factor 2, and TNF
receptor type 1-associated death domain protein, RIP
plays a pivotal role in regulating NF-B (Meylan and
Tschopp, 2005; Jackson-Bernitsas et al., 2007). RIP also inter-
acts with the epidermal growth factor receptor and thereby
contributes to activation of NF-B by epidermal growth
factor (Habib et al., 2001). In cell models, RIP is critical in
NF-B activation induced by the death receptor TNF-related
apoptosis-inducing ligand (TRAIL) and by DNA-damaging
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agents (Lin et al., 2000; Meylan and Tschopp, 2005). RIP also
contributes to TNF-induced activation of c-Jun NH2-termi-
nal kinase and extracellular signal-related kinase (ERK)
(Devin et al., 2003). Furthermore, RIP interacts with FAK to
suppress apoptosis and contributes to TNF-–mediated ac-
tivation of NF-B (Kurenova et al., 2004). In vivo, RIP plays
a role in apoptosis as supported by the findings in RIP null
mice (Kelliher et al., 1998). Thus, RIP seems to participate in
both cell survival and cell death pathways (Meylan and
Tschopp, 2005); however, its ability to interplay between cell
death receptor pathways and survival pathways has not
been explored. Previously, we showed that an altered fi-
bronectin matrix (Kapila et al., 1997) induces anoikis of hu-
man SCC cells by suppressing integrin  v-mediated phos-
phorylation of FAK and ERK (Kamarajan and Kapila, 2007).
In this study, we examined the link between the death
receptor and survival integrin/FAK signaling pathways in
regulating anoikis. Identification of key signaling mediators
in this process could be useful in identifying therapeutic
targets for the treatment of SCC.
MATERIALS AND METHODS
Cell Lines and Culture
The highly invasive human oral SCC cell line HSC-3 (Owens et al., 1995) was
kindly provided by Randy Kramer (University of California, San Francisco,
San Francisco, CA). The human SCC cell line UM-SCC1 was a gift from Tom
Carey (University of Michigan, Ann Arbor, MI). RIP/ and RIP/ mouse
embryonic fibroblasts (MEFs) were kindly provided by Philip Leder and
Michelle Kelliher (Harvard Medical School, Boston, MA). Wild-type and
FAK/ MEFs were from American Type Culture Collection (Manassas, VA).
Fibroblasts from wild-type (Fas) and homozygous lymphoproliferation spon-
taneous mutation (Faslpr) mice (000482; The Jackson Laboratory, Bar Harbor,
ME) were isolated from skin by standard methods. Cells were maintained in
a 5% CO2 atmosphere at 37°C in DMEM (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin.
Plasmids and DNA Constructs
The FAK construct (pRc/CMV-FAKHA) was provided by Steven K. Hanks
(Vanderbilt University, Nashville, TN). FLAG- or myc-tagged wild-type RIP
and myc-tagged RIP deletion mutants, including RIP1-558 and RIP559-671, have
been described previously (Inohara et al., 2000; Lin et al., 2006). The FasGFP
(pEF-GFPFas) construct was provided by Ze’ev A. Ronai (Burnham Institute,
La Jolla, CA).
Inducing Anoikis with an Altered Fibronectin Matrix
Cells were treated with a recombinant fibronectin (FN) protein (Kapila et al.,
1999) containing an alternatively spliced V region and a mutant, nonfunc-
tional [VH] high-affinity heparin-binding domain (Barkalow and Schwar-
zbauer, 1991). This protein also contains the RGD cell binding site and the
alternatively spliced EIIIA domain. The mutant VH protein (mtFN) alters
the fibronectin matrix, rendering it dysfunctional and inducing anoikis
(Kapila et al., 1999; Tafolla et al., 2005; Kamarajan and Kapila, 2007; Joo et al.,
2008). Thus, anoikis conditions were set by treatment with VH or mtFN.
Flow Cytometry
The percentage of apoptotic cells was determined by flow cytometry. In brief,
cells were grown in 12-well plates and treated as indicated. Adherent cells
were detached by incubation with enzyme-free dissociation buffer (Invitro-
gen), pelleted by centrifugation, and stained with annexin V-fluorescein iso-
thiocyanate (FITC) or annexin V-phycoerythrin (BD Biosciences Pharmingen,
San Diego, CA) for analysis by flow cytometry (FACSDiVA Cell Sorter; BD
Biosciences, Franklin Lakes, NJ). For surface expression, cells were washed
twice with phosphate-buffered saline (PBS) and stained with monoclonal
antibodies (mAbs) to Fas (mAb 3061), FasL (mAb 3912; Millipore Bioscience
Research Reagents, Temecula, CA and sc-71097; Santa Cruz Biotechnology,
Santa Cruz, CA), TNFR1 (sc-73195; Santa Cruz Biotechnology), or DR5 (sc-
53688; Santa Cruz Biotechnology), followed by secondary antibodies conju-
gated with FITC, and then analyzed and quantified by FACScan (BD Bio-
sciences). Fold changes were assessed relative to control. DNA fragmentation
was measured using the cell death assay kit (11774425001; Roche Molecular
Systems, Alameda, CA).
Immunoprecipitation and Immunoblot Analysis
For immunoprecipitation experiments, cells were treated as indicated, and
lysed in radioimmunoprecipitation assay lysis buffer containing protease
inhibitors (50 mM Tris/HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deoxy-
cholate, 150 mM NaCl, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride,
1% protease inhibitor cocktail [P8340; Sigma-Aldrich, St. Louis, MO), 1 mM
Na3VO4, and 1 mM NaF), and immunoprecipitation was carried out by
standard methods. Western blotting was performed with various antibodies.
Antibodies for Fas (sc-8009 and sc-715), c-myc (sc-40), green fluorescent
protein (GFP; sc-8334, sc-9996), and -actin (sc-1615) were from Santa Cruz
Biotechnology. Antibodies for FAK (05-182), caspase-8 (9746), FLAG (M2-
A8592), and RIP (610459) were from Millipore (Billerica, MA), Cell Signaling
Technology (Danvers, MA), Sigma-Aldrich, and BD Biosciences Pharmingen,
respectively. Fas-associated death domain (FADD) antibody was from Milli-
pore. All other reagents were from Sigma-Aldrich.
Transient Transfection of Cells and Establishment of
Stable Cell Lines
Cells at 60–70% confluence in twelve- or six-well plates were transiently
transfected with small interfering RNA (siRNA) for Fas or RIP or with cDNA
for Fas (1.0 g), FAK (1.0 g), FLAG-tagged RIP (1.0 g), myc-tagged wild-
type RIP, RIP deletion mutants (1.5 g), or control vectors in 0.5 or 1 ml of
serum-free medium containing Lipofectamine Plus (Invitrogen) by standard
methods. Transfection efficiency was assessed by measuring the levels of Fas,
FAK, FLAG, RIP, or c-myc in transfected and control cells by Western blotting
or GFP fluorescence, and it ranged between 60 and 70%. For the production
of stably transfected cell lines, Faslpr cells were transfected with pEF-GFP
(Addgene plasmid, 11154) or pEF-GFP-Fas in 0.5 ml of serum-free media
containing Lipofectamine Plus by standard methods. The cells were split
1:20 into fresh medium at 24 h after transfection. Transfected cells were
cultured in selective medium containing 300 g/ml geneticin antibiotic
(10131-035; Invitrogen) for an additional 10 d. The surviving cell colonies
were picked and propagated in a fresh 12-well dish before testing for
transgene expression.
Statistical Analysis
In general, values are expressed as means  SD. Intergroup differences were
determined by two-way analysis of variance and Scheffe´’s multiple-compar-
ison test. Statistical significance was defined as *, #p  0.01. All experiments
were repeated at least three times.
RESULTS
Anoikis Mediated by Fas/CD95 Signaling, Triggers
Association of RIP with Fas and Dissociation of RIP
from FAK
To determine whether death domain containing receptors
are involved in anoikis of SCC cells, we examined the levels
of the major classes of death domain-containing receptors
Fas, TNFR1, and DR5 under anoikis conditions. Anoikis
conditions were induced by treatment with altered fibronec-
tin (mtFN) or incubation under suspension culture condi-
tions, and then cell surface expression of the death domain
containing receptors was specifically assessed by flow cy-
tometry. Fas and its cognate ligand, FasL, but not TNFR1
levels were increased significantly (Figure 1A). Although
DR5 expression was increased under anoikis conditions, the
degree of induction was less than that of Fas. Suppression of
Fas with neutralizing antibodies or silencing Fas with siRNA
rescued SCC cells from anoikis, as assessed morphologically
and by flow cytometry (Figure 1A, right; and B, left and
middle). In addition, Fas suppression inhibited DNA frag-
mentation in SCC cells (Figure 1B, right). Suppression of Fas
by siRNA was confirmed by Western blot analysis. Further-
more, death-inducing signaling complexes were formed
under anoikis conditions, as evidenced by the increased
association between Fas and FADD and between Fas and
caspase-8, indicating Fas activation (Figure 1C).
To determine how anoikis modulates survival signaling in
the context of Fas activation, we investigated the role of
FAK. Because RIP interacts with FAK and Fas indepen-
dently to regulate survival and death signaling pathways,
we examined those interactions in SCC cells under anoikis
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conditions. Interactions with FAK decreased, whereas
those with Fas increased (Figure 1D), suggesting that RIP
shuttles back and forth between FAK and Fas to regulate
anoikis.
Fas Signaling and Association with RIP Is Required for
Anoikis
To determine the role of Fas in regulating anoikis and to
explore interactions between cell survival and cell death sig-
naling pathways, we examined Faslpr fibroblasts under anoikis
conditions. The cells were resistant to anoikis as assessed mor-
phologically and by flow cytometry (Figure 2A), showing Fas
mediates anoikis. In contrast, Faslpr fibroblasts overexpressing
Fas became sensitized to apoptosis under anoikis conditions
(Figure 2B), confirming that Fas is an important mediator in
matrix-regulated anoikis. Coimmunoprecipitation data con-
firmed that RIP dissociated from FAK and associated with Fas
to mediate anoikis (Figure 2C). Overexpression of GFP-Fas was
confirmed by Western blot analysis, and its membrane local-
ization was also confirmed in GFP-Fas–transfected cells (Figure
2, B and C). Furthermore, Faslpr cells were stably transfected
with empty vector or Fas and resultant clones were designated
as GFP-Faslpr and GFP-Fas-Faslpr, respectively. Fas overexpres-
sion was confirmed at the protein level using Western blotting
against the GFP tag (Figure 2D, inset). Fas overexpression
resulted in a significant increase in DNA fragmentation under
anoikis conditions, whereas, cells expressing empty vector did
not (Figure 2D).
RIP Shuttles between FAK and Fas to Regulate Anoikis
We hypothesized that RIP shuttles between a FAK-bound
state to promote survival signaling and a Fas-bound state to
promote death signaling pathways. To examine this possi-
bility, we tested FAK-null (FAK/) MEFs under anoikis
conditions. The FAK/ cells were highly sensitive to
anoikis. Overexpression of FAK in transfected FAK/ cells
inhibited anoikis (Figure 3A). FAK expression in the trans-
fected cells was confirmed by Western blot analysis (Figure 3A,
inset). Next, we examined the association of RIP with FAK and
Fas. Consistent with our hypothesis, RIP strongly associated
with FAK upon FAK overexpression, and this association was
diminished by treatment with mtFN under anoikis conditions
(Figure 3B). Conversely, interactions between Fas and RIP
were not apparent upon FAK overexpression, but they in-
creased in response to treatment with mtFN (Figure 3B).
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Figure 1. Anoikis induces the Fas signaling pathway. (A)
Surface expression of Fas, DR5, or TNFR1 (left) or FasL
(middle) in SCC cells (HSC-3) after treated with intact
fibronectin control (FN) or mutant fibronectin (mtFN; 50
g/ml) for 3 h or suspension culture for 16 h. Cells were
stained with antibodies and analyzed and quantified using
a flow cytometer. Right, cells were pretreated with Fas-
neutralizing antibodies and treated with mtFN (50 g/ml)
for 16 h. Apoptosis (annexin V staining) was assessed by a
fluorescence-activated cell sorting (FACS)-based assay. (B)
Left, phase-contrast images of SCC cells (HSC-3) after
transfection with Fas siRNA (100 nM) and treated with
control or mtFN (50 g/ml) for 16 h. Middle, apoptosis
(annexin V staining) was assessed by an FACS-based as-
say. Inset, immunoblot showing the levels of Fas in SCC
cells (HSC-3) after transfection with Fas siRNA or control siRNA (ctl siRNA; 100 nM). -Actin served as loading control. Right, fold change
of DNA fragmentation in SCC cells (HSC-3) after transfection with Fas siRNA (100 nM) and treated with control or mtFN (50 g/ml) for 8
or 16 h. (C and D) SCC cells (HSC-3) were treated with control or mtFN (50 g/ml) for 3 h, and lysates were immunoprecipitated and
immunoblotted as indicated. Immunoglobulin G (IgG), in the cases when it was used, it did not overlap with the proteins of interest. Bars,
50 m. *, #p  0.01.
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RIP Is a Proapoptotic Transducer of Fas-mediated
Anoikis
To further confirm the role of RIP in Fas-mediated anoikis, we
tested wild-type and RIP-null (RIP/) MEFs under anoikis
conditions. Like SCC cells, the RIP/ wild-type cells under-
went anoikis; however, the RIP/ cells were resistant to
anoikis (Figure 3C). Forced expression of RIP in RIP/ cells
significantly increased anoikis (Figure 3D). These data indicate
that RIP deficiency makes cells resistant to anoikis and that RIP
is a proapoptotic mediator in Fas-mediated anoikis. Further-
more, silencing RIP with siRNA rescued SCC cells from
anoikis, confirming that RIP is an important mediator in ma-
trix-regulated apoptosis (Figure 3E, top and bottom).
RIP’s Death Domain Is Critical to Mediating Anoikis and
Shuttling between Fas and FAK
To identify the RIP domain that mediates anoikis, we tested
RIP deletion mutants (Figure 4A) and examined their ability
to modulate anoikis induced by mtFN in SCC and RIP/
cells. Wild-type RIP and a RIP mutant containing only the
death domain (aa 559-671; RIP559-671) increased matrix-induced
apoptosis equally, whereas a RIP mutant containing the kinase
and intermediate domains (aa 1-558; RIP1-558) did not induce
anoikis beyond controls (Figure 4, B and C). RIP expression in
transfected SCC and RIP/ cells was individually optimized
and confirmed by Western blot analysis (Figure 4, B and C).
Together, these data indicate that RIP’s death domain is suffi-
cient and essential in matrix-induced cell death.
To identify the RIP domains that are critical for binding to
FAK and Fas, and thus for RIP’s shuttling function, we
tested the ability of the RIP mutants to form complexes with
Fas and FAK using coimmunoprecipitation experiments in
transfected RIP/ cells. Under anoikis conditions, cells
expressing wild-type RIP and RIP559-671 formed complexes
with Fas to a greater extent than those expressing RIP1-558
(Figure 4C). In addition, the lowest FAK and RIP complexes
were formed in the absence of the RIP kinase domain, un-
derscoring the critical role of this domain in FAK–RIP inter-
actions. Together, these data demonstrate that RIP’s death
domain is the critical RIP region for complexing with Fas,
whereas the kinase domain is the critical RIP region for
complexing with FAK in regulating anoikis and shuttling
between Fas and FAK. Based on these findings, we propose
a model for RIP’s dual role in regulating survival and
anoikis signaling pathways (Figure 4D).
DISCUSSION
This study shows that RIP is a key signaling and shuttling
protein that communicates with both integrin/FAK survival
signals and Fas death signals in anoikis. Furthermore, al-
though previous reports show that RIP interacts with FAK
or Fas under separate conditions, our data reveal for the first
time that RIP connects the two pathways. Thus, RIP could be
an important early and upstream target for regulating
anoikis in SCC and different cell systems. Treatment with
mtFN, which alters the fibronectin matrix and creates con-
ditions that lead to anoikis, induced FasL expression and
subsequent Fas induction and activation by mediating the
formation of death-inducing signaling complexes. Up-regu-
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Figure 2. Fas signaling and association with
RIP is required for anoikis. (A) Top, phase-
contrast images of wild-type (Fas) and Fas-de-
ficient (Faslpr) fibroblasts after treatment with
mtFN (50 g/ml) for 5 h. Bottom, percentage of
apoptotic cells determined by flow cytometry
after treatment with mtFN (50 g/ml) for 5 h.
(B) Top left, intracellular localization of GFP-
Fas or GFP proteins after transfection with
GFP-Fas or GFP vector controls (1.0 g). Bars,
10 m. Top right, phase-contrast images of
Faslpr fibroblasts after transfection with GFP-
Fas and treatment with mtFN (50 g/ml) for
5 h. Bottom, percentage of apoptotic cells de-
termined by flow cytometry after treatment
with mtFN (50 g/ml) for 5 h. (C) Faslpr fibro-
blasts were transfected with GFP-Fas cDNA
and treated with mtFN (50 g/ml) for 5 h.
Lysates were immunoprecipitated and immuno-
blotted as indicated. (D) Faslpr cells were stably
transfected with empty vector or Fas and result-
ant clones were designated as GFP-Faslpr and
GFP-Fas-Faslpr, respectively. -Fold change of
DNA fragmentation in control (GFP-Faslpr) and
Fas expressing (GFP-Fas-Faslpr) clones after
treated with mutant fibronectin (mtFN; 50 g/
ml) for 16 h. Inset, Fas overexpression was
confirmed at the protein level using Western
blot against GFP. -Actin served as loading
control. Bars, 50 m for phase-contrast im-
ages. *, #p  0.01.
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lation of FasL and Fas and formation of the death-inducing
signaling complex are key signals that initiate apoptosis by
agents such as agonistic Fas antibody, cisplatin, and meth-
otrexate in different cancer cells (Friesen et al., 1996; Uslu et
al., 1997). The elevated levels of Fas and the formation of the
death-inducing signaling complex under anoikis conditions,
and the rescue of cells from anoikis by Fas siRNA treatment
or Fas deficiency, further confirmed that anoikis is mediated
by the Fas/CD95 death receptor pathway. These findings
indicate that Fas activation and formation of the death-
inducing signaling complex are critical for anoikis. Although
DR5 induction was relatively low, the possibility of DR5
involvement in mediating anoikis is not ruled out.
Detachment of epithelial cells and SCC cells from their
substratum or matrix leads to decreased integrin/FAK-me-
diated survival signaling, resulting in anoikis (Frisch and
Francis, 1994; Zhang et al., 2004). In esophageal SCC cells,
suppression of FAK promotes anoikis and suppresses metas-
tasis (Duxbury et al., 2004), whereas overexpression of FAK
correlates with tumor invasiveness and metastasis (Miyazaki et
al., 2003). FAK in general transduces integrin-mediated signals
that regulate survival and migration (Parsons, 2003).
Because decreased FAK survival signals and activation of
Fas death signals were involved in matrix-induced apopto-
sis in SCC cells, we hypothesized that these two pathways
communicate through a shuttling protein. Indeed, RIP func-
tioned in that capacity. Under anoikis conditions, RIP dis-
sociated from FAK and formed a complex with Fas, whereas
under survival conditions, it dissociated from Fas and com-
plexed with FAK. In FAK/ cells, reintroduction of FAK
promoted survival and allowed RIP to complex with FAK;
under anoikis conditions, however, RIP-FAK complex levels
were decreased. RIP/ cells were resistant to anoikis, and
reintroduction of RIP into these cells sensitized them to
anoikis. RIP reintroduction also enabled the formation of
RIP–FAK complexes; under anoikis conditions, those com-
plexes were reduced, and RIP–Fas complexes became more
abundant. These findings demonstrate that RIP shuttles be-
tween Fas and FAK to regulate anoikis.
In cell death pathways, RIP is activated and cleaved upon
treatment with TNF, Fas, or TRAIL (Lin et al., 1999; Martinon
et al., 2000). However, RIP can also participate in survival
pathways (Meylan and Tschopp, 2005). RIP/ cells are
resistant to staurosporine- and cisplatin-induced apoptosis
(Kurenova et al., 2004) but are sensitive to TNF-induced
apoptosis (Cusson et al., 2002), suggesting a dual role for RIP
in apoptosis. In this study, we showed that anoikis condi-
tions trigger the dissociation of RIP from FAK and the
formation of a RIP–Fas complex that initiates cell death,
indicating that RIP plays a proapoptotic role in anoikis.
To further confirm that RIP acts as a proapoptotic or
prosurvival mediator, we tested RIP/ and RIP/ fibro-
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Figure 3. RIP shuttles between FAK and Fas to regulate anoikis. (A) Top, phase-contrast images of FAK/MEFs after treatment with mtFN
(50 g/ml) for 16 h. Bottom, percentage of apoptotic cells determined by flow cytometry after transfection with FAK (1.0 g) or vector control
and treatment with mtFN (50 g/ml) for 16 h. Inset, immunoblots showing the FAK levels in cells after transfection with FAK (1.0 g) or
vector control. (B) FAK/ MEFs were transfected with FAK cDNA and treated with mtFN (50 g/ml) for 3 h. Lysates were immunopre-
cipitated and immunoblotted as indicated. (C) Top, phase-contrast images of wild-type (RIP/) and RIP/ MEFs after treatment with
mtFN (50 g/ml) for 5 h. Bottom, percentage of apoptotic cells determined by flow cytometry after treatment with mtFN (50 g/ml) for 5 h.
(D) Percentage of apoptotic cells in RIP/ cells after transfection with FLAG-RIP (1.0 g) and treated with mtFN (50 g/ml) for 5 h. Inset,
immunoblot showing RIP levels after transfection with FLAG-RIP (1.0 g). (E) Percentage of apoptotic cells in SCC cells (top, HSC-3; bottom,
UM-SCC1) determined by flow cytometry after transfection with RIP siRNA (50 n) and treated with mtFN (50 g/ml) for 16 h. Inset,
immunoblot showing RIP levels after transfection with RIP siRNA (50 n). Bars, 50 m. *, #p  0.01.
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blasts under anoikis conditions. RIP/ cells were resistant
to anoikis; however, reintroduction of RIP rendered them
sensitive to anoikis. Thus, RIP is a proapoptotic mediator
essential for anoikis. To further demonstrate that RIP also
regulates cell survival pathways, we tested its role in
FAK/ MEFs, which are highly sensitive to RIP-mediated
apoptosis. Ectopic expression of FAK restored the interac-
tion of RIP with FAK and the concomitant dissociation of
RIP from Fas, thereby rescuing cells from anoikis and con-
firming that RIP interacts with both death and survival
signals. Thus, FAK overexpression in SCC cells prevents the
interaction of RIP with Fas, making cells resistant to death
receptor-induced apoptosis. Given its ability to mediate both
cell death and cell survival pathways, RIP could be a poten-
tial therapeutic target for SCC.
RIP cleavage leads to the inhibition of the NF-B pathway,
thereby potentiating apoptosis (Lin et al., 1999). Therefore,
we hypothesize that NF-B acts downstream of RIP in
anoikis. Consistent with these findings, rituximab sensitizes
cells to apoptosis by increasing Fas expression and inhibit-
ing the NF-B signaling pathway (Vega et al., 2005). Thus,
under anoikis conditions, RIP cleavage may inhibit NF-B
activity to potentiate apoptosis.
The RIP death domain is important for TNF-induced cell
death (Thakar et al., 2006), whereas the kinase domain is
important for survival signals such as those mediated by
ERK (Devin et al., 2003) and the epidermal growth factor
receptor (Habib et al., 2001). Consistent with this finding, we
showed that the RIP deletion mutant containing the death
domain is sufficient to induce anoikis, whereas the RIP mu-
tant containing the kinase and intermediate domains did not
enhance anoikis. Also, the RIP kinase domain mutant
formed the lowest level of complexes with FAK, indicating
the importance of the kinase domain in FAK interactions.
Thus, the RIP death domain is sufficient and essential for
anoikis in SCC cells.
Based on our findings and published literature, we pro-
pose that RIP regulates anoikis by shuttling between the
CD95/Fas-mediated death pathway and the integrin/FAK-
mediated survival pathway (Figure 4D). In the presence of a
prosurvival matrix (i.e., intact fibronectin), FAK and RIP
associate, thereby inhibiting the association of RIP with Fas
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Figure 4. Functional mapping of RIP’s apoptosis-inducing domain in SCC and RIP/ cells. (A) Schematic diagram of wild-type RIP and
RIP mutants. (B) Top, immunoblots showing RIP levels in SCC cells (HSC-3) after transfection with 1.5 g of myc-RIP, myc-RIP1-558, or
myc-RIP559-671. Bottom, percentage of apoptotic cells determined by flow cytometry after treatment with mtFN (25 g/ml) for 16 h. (C) Top,
Immunoblots showing RIP levels in RIP/ cells after transfection with 1.5 g of myc-RIP, myc-RIP1-558, or my-RIP559-671. Middle, percentage
of apoptotic cells determined by flow cytometry after treatment with mtFN (50 g/ml) for 16 h. Bottom, RIP/ cells were transfected as in
top panel and treated with mtFN (50 g/ml) for 3 h. Lysates were immunoprecipitated with Myc and immunoblotted with Fas or FAK.
(D) Model of the dual role of RIP in regulating anoikis and survival. In the presence of a prosurvival matrix (intact fibronectin; FN), FAK and
RIP associate, thereby inhibiting the association of RIP with Fas and formation of the death-inducing signaling complex (Fas, FADD, and
caspase-8) and leading to cell survival through activation of cell survival signals, such as phosphorylation of FAK and ERK. In the presence
of a proapoptotic matrix (mtFN), FAK and RIP dissociate, leading to the association of RIP with Fas and formation of the death-inducing
signaling complex. In parallel, caspase-8 may induce activation of RIP cleavage and activation of other downstream effector caspases, leading
to cell death by anoikis. #p  0.01.
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and leading to cell survival through phosphorylation of FAK
and activation of cell survival signals, such as ERK. Under
anoikis conditions, FAK and RIP dissociate, leading to the
association of RIP with Fas and the formation of the death-
inducing signaling complex. Caspase-8 activates down-
stream effector caspases, and it may also induce RIP cleav-
age leading to cell death. Cleaved RIP may inhibit or
neutralize NF-B and its downstream survival signals. In
addition, inhibition of integrin/FAK signals probably leads
to reduced ERK phosphorylation and further loss of survival
signals.
In conclusion, our findings show that RIP is required for
anoikis induced by the Fas/CD95 death receptor, and RIP
shuttles between Fas and FAK to mediate this mechanism.
Our report supports the notion that therapeutic pharmaceu-
ticals can target RIP as a switch to control cell death or
survival pathways to ultimately regulate normal tissue pro-
cesses and tumorigenesis.
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